Clearwater, FL, September 13, 2023 – dG Medical Group, with a dedication to providing patients, physicians, and clinicians the most advanced and beneficial technology, is launching research studies in the use of Mesenchymal Stem Cell (MSC) Exosomes for a variety of medical conditions. This landmark of an achievement makes it the only product legally permitted to be sold for clinical use through research. [Read more…]
Stem Cell News
BioInformant's coverage of stem cell news includes iPS cells, mesenchymal stem cells, hematopoietic stem cells, neural stem cells and more.
As the first and only market research firm to specialize in stem cell news, BioInformant research has been cited by the Wall Street Journal, Xconomy, AABB, and Vogue Magazine.
Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry news.
Shoreline Biosciences Wins a Comprehensive Summary Judgment Victory on All Claims Brought by Fate Therapeutics and Whitehead Institute on iPSC Generation and Use
September 7, 2023, SAN DIEGO – Shoreline Biosciences, Inc., a biopharmaceutical company developing effective and differentiated cellular immunotherapies based on induced pluripotent stem cells (iPSCs) derived natural killer cells (iNKs) and macrophages (iMACs), today announced a major milestone in its patent litigation with Fate Therapeutics, Inc. and the Whitehead Institute in the U.S. District Court for the Southern District of California. [Read more…]
Despite progress involving the use of induced pluripotent stem cells (iPSCs) within disease modeling and drug discovery applications, it will be a long path to achieve the broad-scale use of iPSC-derived cell types in human patients. [Read more…]
BlueWhale Bio Science Team led by world-renowned immunotherapy pioneers Carl June and James Riley of University of Pennsylvania
BlueWhale Bio technology platform aims to bring cell and gene therapy benefits to patients faster and at lower cost
Investors include Danaher Ventures, Novalis LifeSciences, Marshall Wace, Hillhouse Capital
PeptiGrowth Inc. (Headquarters: Chiyoda-ku, Tokyo, President: Jiro Sugimoto) has successfully developed a novel synthetic peptide called “VEGF alternative peptide (VEGFR2 agonist)” which has equivalent function to recombinant VEGF (Vascular Endothelial Growth Factor). This product will be on the market at the end of September 2023. [Read more…]